Baseline Plus: Ideally suited for orphan drug post-approval studies

Baseline Plus provided the ideal platform to enable a specialised European Pharma company to run a post-approval safety study as a licensing requirement. However, managing data from large number of sites around the world created a major challenge.

...Download the full case study to learn more. 

More Case Studies

  • Real-world studies in complex treatments

    Cisiv’s EDC platform, Baseline Plus, is built specifically to meet the...

  • Designing and conducting a successful HEOR study

    A leading global pharmaceutical company was looking for a...

  • Optimising post-approval research: using technology for efficient and cost-effective studies

    A large global Pharma company was required to run a complex global...

incisive solutions decisive results

©Cisiv 2021 - All Rights Reserved. Registered Company Number : 3110147

Website by 3Men²